MeSH | Lymphoproliferative Disorders (D008232)

Lymphoproliferative Disorders D008232

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders

Description

Disorders characterized by proliferation of lymphoid tissue, general or unspecified. MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (21)

Agammaglobulinemia
29 drugs (27 approved, 2 experimental)

Autoimmune Lymphoproliferative Syndrome
5 approved drugs

Castleman Disease
23 drugs (20 approved, 3 experimental)

Granuloma
39 drugs (30 approved, 9 experimental)

Heavy Chain Disease

Immunoblastic Lymphadenopathy
1 approved drug

Immunoglobulin Light-chain Amyloidosis
55 drugs (41 approved, 14 experimental)

Immunoproliferative Small Intestinal Disease

Infectious Mononucleosis
7 drugs (4 approved, 3 experimental)

Leukemia, Hairy Cell
91 drugs (62 approved, 29 experimental)

Leukemia, Lymphoid
153 drugs (88 approved, 65 experimental)

Lymphangiomyoma
1 approved drug

Lymphoma
1032 drugs (407 approved, 625 experimental)

Macrophage Activation Syndrome
8 drugs (7 approved, 1 experimental)

Marek Disease

Multiple Myeloma
918 drugs (315 approved, 603 experimental)

Plasmacytoma
89 drugs (60 approved, 29 experimental)

Sarcoidosis
55 drugs (42 approved, 13 experimental)

Sezary Syndrome
124 drugs (81 approved, 43 experimental)

Tumor Lysis Syndrome
4 approved drugs

Waldenstrom Macroglobulinemia
177 drugs (96 approved, 81 experimental)

Approved Indicated Drugs (1)

Leniolisib (Joenja)

Phase 4 Indicated Drugs (5)

cyclophosphamide (cytoxan)

doxorubicin (Doxil)

fludarabine (fludara)

hepatitis b vaccine (recombinant) (Recombivax)

rituximab (rituxan)

Phase 3 Indicated Drugs (12)

allogeneic lymphocytes

amitriptyline (elavil)

baclofen (lioresal)

darbepoetin alfa (aranesp)

epoetin (Epogen)

ferrous sulfate

ibrutinib (imbruvica)

iron dextran (INFeD)

ketamine (ketalar)

Phase 2 Indicated Drugs (48)

acalabrutinib (calquence)

allogeneic hematopoietic stem cells (Hemacord)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)

autologous hematopoietic stem cells

autologous immunoglobulin idiotype-klh conjugate vaccine

bendamustine (treanda)

bortezomib (velcade)

brentuximab vedotin (adcetris)

chloroprednisone

cisplatin (platinol)

cyclosporine (sandimmune)

cytarabine (cytosar-u)

etoposide (vepesid)

everolimus (zortress)

gemcitabine (gemzar)

hydroxyurea (hydrea)

immune globulin (human) (Gamastan)

interferon alpha-2a (roferon-a)

interferon alpha-2b (Intron-A)

leflunomide (arava)

lisocabtagene maraleucel (Breyanzi)

lmp-specific cytotoxic t-lymphocytes

lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)

melphalan (alkeran)

mesna (mesnex)

methylprednisolone (medrol)

mycophenolate (CellCept)

naltrexone (revia)

nivolumab (opdivo)

obinutuzumab (gazyva)

pacritinib (Vonjo)

pentostatin (nipent)

prednisone (meticorten)

sargramostim (leukine)

sirolimus (rapamune)

sodium phenylbutyrate (buphenyl)

tacrolimus (prograf)

tafasitamab (Monjuvi)

tretinoin (Retin-A)

valganciclovir (Valcyte)

vincristine (oncovin)

zidovudine (retrovir)

Phase 1 Indicated Drugs (24)

allogeneic transplant donor lymphocytes, depleted of tcr-αβ t cells and b cells; enriched for nk cells and tcrγδ t cells

autologous ebv specific cytotoxic t lymphocytes

autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine

barf1-specific cytotoxic t-lymphocytes

bevacizumab (avastin)

clofarabine (clolar)

dimethylarsinous glutathione

ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine

ebna1-specific cytotoxic t-lymphocytes

EBV Specific T-Lymphocytes

ganciclovir (cytovene)

icaspase9-transduced t cells

phenethyl isothiocyanate

pyrimethamine (daraprim)

vandetanib (caprelsa)

Other Experimental Indicated Drugs (11)

aprepitant (Emend)

dapsone (aczone)

epstein-barr virus cytotoxic t lymphocytes

fentanyl (Innovar)

methadone (methadose)

monoclonal antibody cd20

ondansetron (zofran)

oxycodone (oxycontin)

plerixafor (mozobil)

Organization Involved with Phase 4 Indications (3)

University of Brescia

University of Lorraine

University of Milan

Organization Involved with Phase 3 Indications (17)

Atara Biotherapeutics

Department of Defense

Gruppo Italiano Trapianto di Midollo Osseo

Harvard University

Ludwig Maximilians University

National Cancer Institute (NCI)

Stanford University

Sundsvall Hospital

University of California, Los Angeles

University of Edinburgh

University of Michigan

University of Minnesota

University of Pennsylvania

Organization Involved with Phase 2 Indications (48)

AIDS Malignancy Consortium

American Cancer Society, Inc.

Baylor University

Boston University

Case Western Reserve University

Celularity, Inc.

City of Hope National Medical Center

Cornell University

Fondazione Progetto Ematologia

Fudan University

HemaQuest Pharmaceuticals

Humboldt University

Juno Therapeutics, Inc.

Korea Research Institute of Bioscience & Biotechnology

Kuur Therapeutics

Maisonneuve-Rosemont Hospital

Methodist Cancer Center, Houston, Texas

Millennium Pharmaceuticals

National Heart, Lung, and Blood Institute (NHLBI)

Northside Hospital, Inc.

Northwestern University

Ohio State University

Rutgers University

San Bortolo Hospital, Vicenza

Seattle Genetics

State University of New York, Buffalo

The University of Texas, Dallas

Thomas Jefferson University

University of California, San Diego

University of California, San Francisco

University of Chicago

University of Florida

University of Medicine and Dentistry of New Jersey

University of Miami

University of Montreal

University of North Carolina at Chapel Hill

University of Rochester

University of Southern California

University of Texas at Houston

University of Toronto

University of Ulsan

University of Washington

Viracta Therapeutics, Inc.

Washington University in St. Louis

Wayne State University

Organization Involved with Phase 1 Indications (21)

Arno Therapeutics

Cancer Research UK

Children's National Medical Center

Fujian Medical University

Geron Corporation

Johns Hopkins University

National Institute of Allergy and Infectious Diseases (NIAID)

National Institutes of Health (NIH)

New York Medical College

Ohio University

University of Alabama, Birmingham

University of Birmingham

University of Colorado, Denver

University of London

University of Utah

University of Wisconsin

Organization Involved with Other Experimental Indications (4)

University of Liverpool

Upstate Carolina

Vanderbilt University

Hierarchy Tree View

MeSH
ICD-10

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.